The use of this modeling approach is the heart of our work, particularly in the development of stable and robust QSAR models that can effectively predict inhibitory activity against
reverse transcriptase and thus contribute to the development of new molecules that inhibit this enzyme.
The two main biochemical mechanisms leading to NRTI (nucleoside analogue
reverse transcriptase inhibitor) resistance are:
Other factors associated with severe hepatotoxicity in this study were use of nevirapine-containing drugs, which were associated in those taking a nonnucleoside
reverse transcriptase inhibitor with both early (OR 4.
Currently
reverse transcriptase inhibitors represent over 50% of the global sales of HIV drugs which in 2004 was in excess of US$6 billion.
International collaborative study to compare
reverse transcriptase PCR assays for detection and genotyping of noroviruses.
Nucleoside/Nucleotide
reverse transcriptase inhibitors (nukes): These medications interfere with viral
reverse transcriptase by acting as "fake building blocks" that disrupt the creation of proviral DNA needed to take over the infected cell to build new viruses (see #2 in diagram).
Other factors associated with severe hepatotoxicity in this study were use of nevirapine-containing drugs, which were associated in those taking a non-nucleoside
reverse transcriptase inhibitor with both early (OR 4.
For more than 10 years, drug discovery efforts have concentrated on relatively few viral targets:
reverse transcriptase (RT) and protease (PR).
The Food and Drug Administration has issued an advisory against taking the supplement with protease inhibitors or non-nucleoside
reverse transcriptase inhibitors.
The structure of the telomerase protein resembles that of
reverse transcriptase, an enzyme used by HIV and other retroviruses, report Joachim Lingner, a Howard Hughes Medical Institute investigator at the University of Colorado in Boulder, and his colleagues in the April 25 Science.
According to Chimerix deal, Merck will have to develope and commercialize CMX157, an investigational oral nucleoside
reverse transcriptase inhibitor which is presently in Phase I clinical development.
